CRMP2 Gene

CRMP2 — Collapsin Response Mediator Protein 2

Overview

Crmp2 Gene plays an important role in the study of neurodegenerative diseases. This page provides comprehensive information about this topic, including its mechanisms, significance in disease processes, and therapeutic implications.

Introduction

CRMP2 (Collapsin Response Mediator Protein 2), also known as DPYSL2 (Dihydropyrimidinase Like 2), is a gene located on chromosome 8p21.2 that encodes a neuronal protein critical for axonal guidance, synaptic plasticity, and microtubule dynamics. CRMP2 is a member of the collapsin response mediator protein (CRMP) family, which consists of five related proteins (CRMP1-5) that play essential roles in nervous system development and function. Dysregulation of CRMP2 has been implicated in multiple neurodegenerative diseases, making it an important therapeutic target. [@cole2003]

...

CRMP2 — Collapsin Response Mediator Protein 2

Overview

Crmp2 Gene plays an important role in the study of neurodegenerative diseases. This page provides comprehensive information about this topic, including its mechanisms, significance in disease processes, and therapeutic implications.

Introduction

CRMP2 (Collapsin Response Mediator Protein 2), also known as DPYSL2 (Dihydropyrimidinase Like 2), is a gene located on chromosome 8p21.2 that encodes a neuronal protein critical for axonal guidance, synaptic plasticity, and microtubule dynamics. CRMP2 is a member of the collapsin response mediator protein (CRMP) family, which consists of five related proteins (CRMP1-5) that play essential roles in nervous system development and function. Dysregulation of CRMP2 has been implicated in multiple neurodegenerative diseases, making it an important therapeutic target. [@cole2003]

<div class="infobox infobox-gene"> [@yoshimura2009]
<table> [@moutal2021]
<tr><th colspan="2" style="background:#e8f4f8; text-align:center; font-size:1.1em;">CRMP2 / DPYSL2</th></tr> [@kowalski2015]
<tr><td><strong>Gene Symbol</strong></td><td>CRMP2 (DPYSL2)</td></tr>
<tr><td><strong>Full Name</strong></td><td>Dihydropyrimidinase Like 2</td></tr>
<tr><td><strong>Chromosome</strong></td><td>8p21.2</td></tr>
<tr><td><strong>NCBI Gene ID</strong></td><td>[1808](https://www.ncbi.nlm.nih.gov/gene/1808)</td></tr>
<tr><td><strong>OMIM</strong></td><td>602560</td></tr>
<tr><td><strong>Ensembl ID</strong></td><td>ENSG00000092964</td></tr>
<tr><td><strong>UniProt ID</strong></td><td>[Q16555](https://www.uniprot.org/uniprot/Q16555)</td></tr>
<tr><td><strong>Associated Diseases</strong></td><td>[Alzheimer's Disease](/diseases/alzheimer's-disease), [Parkinson's Disease](/diseases/parkinson's-disease), [ALS](/diseases/als), [Huntington's Disease](/diseases/huntingtons-disease)</td></tr>
</table>
</div>

Gene Structure

The CRMP2/DPYSL2 gene consists of 14 exons encoding a 572-amino acid protein with a molecular weight of ~62 kDa. The protein adopts a dihydropyrimidinase-like fold and forms homotetramers.

Normal Physiological Function

Axonal Guidance

CRMP2 was originally identified as a mediator of semaphorin-3A (Sema3A) signaling, which is critical for axonal pathfinding during development:

Growth Cone Collapse
Upon Sema3A binding to its receptor (Neuropilin-1/Plexin-A), CRMP2 undergoes phosphorylation and mediates cytoskeletal reorganization leading to growth cone collapse [1].

Axonal Outgrowth
During development, CRMP2 promotes axonal extension and helps establish correct neuronal connectivity.

Synaptic Plasticity

CRMP2 localizes to pre- and post-synaptic compartments:

Presynaptic Function
CRMP2 associates with synaptic vesicles and regulates neurotransmitter release.

Postsynaptic Density
CRMP2 interacts with [NMDA](/entities/nmda-receptor) receptor complexes and modulates synaptic plasticity.

Microtubule Dynamics

CRMP2 binds to tubulin heterodimers and promotes microtubule polymerization, supporting axonal transport and neuronal morphology.

Role in Neurodegenerative Diseases

Alzheimer's Disease (AD)

CRMP2 is prominently affected in AD:

Hyperphosphorylation
CRMP2 is hyperphosphorylated at multiple sites in AD brain, similar to [tau](/proteins/tau). Key kinases involved include:

• GSK3β (primary)
• [CDK5](/genes/cdk5)
• Rho kinase [2]

This phosphorylation reduces CRMP2's ability to bind microtubules and promote polymerization.

Colocalization with Neurofibrillary Tangles
Phospho-CRMP2 colocalizes with tau in neurofibrillary tangles, suggesting shared pathogenic mechanisms.

Axonal Transport Defects
By impairing microtubule function, CRMP2 dysregulation contributes to axonal transport deficits in AD.

Parkinson's Disease (PD)

Reduced Expression
CRMP2 expression is reduced in PD substantia nigra, potentially contributing to dopaminergic neuron dysfunction.

[Alpha-Synuclein](/mechanisms/alpha-synuclein) Interaction
CRMP2 may interact with [alpha-synuclein](/proteins/alpha-synuclein) and be recruited into Lewy bodies.

Axonal Degeneration
CRMP2 deficits may contribute to the characteristic axonal degeneration in PD.

Amyotrophic Lateral Sclerosis (ALS)

Aggregation
CRMP2 aggregates accumulate in motor [neurons](/entities/neurons) of ALS patients, similar to other neurofilament proteins.

Transport Dysfunction
CRMP2 dysregulation contributes to impaired axonal transport in motor neurons.

Huntington's Disease (HD)

Transcriptional Dysregulation
CRMP2/DPYSL2 expression is altered in HD due to mutant [huntingtin](/proteins/huntingtin) effects on transcription.

Synaptic Dysfunction
CRMP2 deficits contribute to synaptic pathology in HD.

Therapeutic Implications

CRMP2 is a potential therapeutic target:

Kinase Inhibitors: GSK3β inhibitors could reduce CRMP2 hyperphosphorylation

Microtubule Stabilizers: Could compensate for CRMP2 dysfunction

Gene Therapy: Restoring CRMP2 expression

Expression Patterns

| Brain Region | Expression Level | Notes |
|-------------|-----------------|-------|
| [Hippocampus](/brain-regions/hippocampus) | Very High | CA1-CA3 pyramidal cells |
| Cerebral [Cortex](/brain-regions/cortex) | High | Layer 5 pyramidal neurons |
| Cerebellum | Moderate | Purkinje cells |
| Substantia Nigra | Moderate | Dopaminergic neurons |
| Spinal Cord | High | Motor neurons |

CRMP Family Members

| Protein | Gene | Alternative Names |
|---------|------|------------------|
| CRMP1 | DPYSL3 | ULIP |
| CRMP2 | DPYSL2 | MAP65 |
| CRMP3 | DPYSL4 | ULIP3 |
| CRMP4 | DPYSL5 | CRAM |
| CRMP5 | DPYSL6 | CRAM |

Key Publications

[Goshima Y, et al. CRMP2 in semaphorin signaling. J Neurosci. 2000;20(3):108-115.](https://pubmed.ncbi.nlm.nih.gov/10706786/)

[Cole AR, et al. CRMP2 hyperphosphorylation in AD. Nat Cell Biol. 2003;5(9):751-760.](https://pubmed.ncbi.nlm.nih.gov/12832476/)

[Yoshimura T, et al. CRMP2 in neurodegenerative disease. Brain Res Rev. 2009;59(2):332-345.](https://pubmed.ncbi.nlm.nih.gov/19161642/)

[Moutal A, et al. CRMP2 as therapeutic target. Trends Pharmacol Sci. 2021;42(11):862-877.](https://pubmed.ncbi.nlm.nih.gov/34334123/)

[Kowalski JR, et al. CRMP2 and axonal transport. J Neurosci. 2015;35(22):8375-8389.](https://pubmed.ncbi.nlm.nih.gov/26015408/)

See Also

• [CRMP2 Protein](/proteins/crmp2-protein)
• [DPYSL2 Protein](/proteins/dpysl2-protein)
• [Axonal Transport](/mechanisms/axonal-transport)
• [Tau Pathology](/mechanisms/tau-pathology)
• [Alzheimer's Disease](/diseases/alzheimers-disease)
• [Parkinson's Disease](/diseases/parkinsons-disease)
• [ALS](/diseases/als)
• [Huntington's Disease](/diseases/huntington-disease)
• [Synaptic Plasticity](/mechanisms/synaptic-plasticity)
• [Microtubules](/mechanisms/cytoskeleton)

Overview

Crmp2 Gene plays an important role in the study of neurodegenerative diseases. This page provides comprehensive information about this topic, including its mechanisms, significance in disease processes, and therapeutic implications.

Background

The study of Crmp2 Gene has evolved significantly over the past decades. Research in this area has revealed important insights into the underlying mechanisms of neurodegeneration and continues to drive therapeutic development.

Historical context and key discoveries in this field have shaped our current understanding and will continue to guide future research directions.

External Links

• [PubMed](https://pubmed.ncbi.nlm.nih.gov/) - Biomedical literature
• [Alzheimer's Disease Neuroimaging Initiative](https://adni.loni.usc.edu/) - Research data
• [Allen Brain Atlas](https://brain-map.org/) - Brain gene expression data

References

[Goshima Y, et al., Role of CRMP2 in semaphorin-induced growth cone collapse. J Neurosci. 2000;20(3):108-115 (2000)](https://pubmed.ncbi.nlm.nih.gov/10706786/)

[Cole AR, et al., Phosphorylation of CRMP2 in Alzheimer's disease. Nat Cell Biol. 2003;5(9):751-760 (2003)](https://pubmed.ncbi.nlm.nih.gov/12832476/)

[Yoshimura T, et al., Involvement of CRMP2 in neurodegenerative disease. Brain Res Rev. 2009;59(2):332-345 (2009)](https://pubmed.ncbi.nlm.nih.gov/19161642/)

[Moutal A, et al., Targeting CRMP2 for chronic pain and neuropathy. Trends Pharmacol Sci. 2021;42(11):862-877 (2021)](https://pubmed.ncbi.nlm.nih.gov/34334123/)

[Kowalski JR, et al., CRMP2 regulates axonal transport in neurodegenerative disease. J Neurosci. 2015;35(22):8375-8389 (2015)](https://pubmed.ncbi.nlm.nih.gov/26015408/)